Acknowledgments
A book like this is the result of the hard work of many. We thank our student line editors for their meticulous work. Footnote 1 We are grateful to Cristine Hutchison-Jones and Chloe Reichel for their administrative support in organizing the conference that gave rise to this book as well as nimbly translating it into a podcast series when disrupted by COVID-19. We are also grateful for Laura Chong’s hard work shepherding all the many pieces of this manuscript.
This book was made possible in part by the generosity and leadership of the Center for Advanced Studies in Biomedical Innovation Law (CeBIL) at the University of Copenhagen and the support of the Novo Nordisk Foundation through a grant for a Collaborative Research Programme (grant agreement number NNF17SA0027784). We thankfully acknowledge the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, with support from the Oswald DeN. Cammann Fund, for conference sponsorship. Finally, of course, we thank the contributors for their thoughtful and important scholarly contributions.
1 Melyssa Eigen, Brian Brooks, and Nathan Rabb.
Open access